文献速递肿瘤 PET/CT核素与放射性配体治疗

CD38特异性免疫PET显像用于多发性骨髓瘤诊断与治疗监测:临床前及首次人体研究

CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-12-27

本研究制备了基于CD38靶向纳米抗体的PET示踪剂[68Ga]Ga-TOHP-CD3813,临床前评估显示其高亲和力(KD 0.0826 nmol/L)、快速血液清除及在CD38阳性移植瘤小鼠模型中的显著摄取(6.50 ± 2.69%ID/g);首次人体试验中2例多发性骨髓瘤患者的[68Ga]Ga-TOHP-CD3813 PET/CT较[18F]FDG PET/CT在多发性骨髓瘤可视化方面有实质性改善。

要点

  • TOHP-CD3813对CD38的KD为0.0826 nmol/L,[68Ga]Ga-TOHP-CD3813可在室温10 min内合成。
  • 临床前CD38阳性移植瘤小鼠模型摄取为6.50 ± 2.69%ID/g,肾脏和膀胱浓聚明显,肝脏摄取中等。
  • 首次人体2例多发性骨髓瘤患者中,[68Ga]Ga-TOHP-CD3813 PET/CT较[18F]FDG PET/CT在多发性骨髓瘤可视化方面有实质性改善。

核心结论

  • [68Ga]Ga-TOHP-CD3813具有高亲和力、特异性及稳健显像能力,可快速特异性聚集于高表达CD38的肿瘤,较[18F]FDG PET/CT在多发性骨髓瘤可视化方面有显著优势,并支持同日PET显像。
  • 初步人体试验结果令人鼓舞,提示其作为优化CD38靶向治疗的伴随诊断工具的潜力。
  • 正在进行的更大规模试验旨在进一步证实这些发现。

研究设计与样本

  • 制备基于CD38靶向纳米抗体CD3813的新型PET示踪剂[68Ga]Ga-TOHP-CD3813,经位点特异性放射性标记用于CD38表达的无创PET显像。
  • 评估[68Ga]Ga-TOHP-CD3813对CD38的亲和力与特异性,并在多发性骨髓瘤及淋巴瘤移植瘤模型中行CD38表达显像。
  • 评估生物分布及肿瘤摄取与CD38表达的关系。
  • 对2例多发性骨髓瘤患者行[68Ga]Ga-TOHP-CD3813 PET显像转化研究,并与[18F]FDG PET/CT头对头比较。
  • 基于动物数据计算剂量学。

主要发现

  • TOHP-CD3813对CD38保持高亲和力,KD为0.0826 nmol/L。
  • [68Ga]Ga-TOHP-CD3813在室温10 min内成功合成,具有最佳放射化学性质。
  • 临床前评估显示快速血液清除、高CD38亲和力及CD38阳性移植瘤小鼠模型显著摄取(6.50 ± 2.69%ID/g)。
  • [68Ga]Ga-TOHP-CD3813在肾脏和膀胱浓聚明显,肝脏摄取中等,提示其作为诊断多发性骨髓瘤的临床PET示踪剂的潜力。
  • 首次人体试验中,[68Ga]Ga-TOHP-CD3813 PET/CT较[18F]FDG PET/CT在多发性骨髓瘤可视化方面有实质性改善。

局限性

  • 正在进行的更大规模试验旨在进一步证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CD38 is a glycoprotein highly specific to multiple myeloma (MM). Therapeutics using antibodies targeting CD38 have shown promising efficacy. However, the efficient stratification of patients who may benefit from daratumumab (Dara) therapy and timely monitoring of therapeutic responses remain significant clinical challenges. To address these issues, we developed a novel nanobody-based PET tracer, [68Ga]Ga-TOHP-CD3813, which exhibits rapid clearance from the blood and rapid accumulation in targeted tumor lesions, facilitating the detection of CD38 expression in murine models of MM and lymphoma. Furthermore, we conducted the world's first-in-human trials using CD38-targeted nanobodies to validate and assess the clinical imaging effectiveness of [68Ga]Ga-TOHP-CD3813 in guiding cancer immunotherapy. MATERIALS AND METHODS: We prepared a new PET imaging probe based on a CD38-targeted nanobody CD3813, [68Ga]Ga-TOHP-CD3813, via the site-specific radiolabeling for noninvasive PET imaging of CD38 expression. [68Ga]Ga-TOHP-CD3813 was assessed for its affinity and specificity to CD38 and its ability to image CD38 expression in MM and lymphoma xenograft models. Biodistribution and the relationship between tumor uptake and CD38 expression were evaluated. Subsequently, we conducted a translational PET imaging of 2 MM patients using [68Ga]Ga-TOHP-CD3813, while compared with [18F]FDG PET/CT head-to-head. Dosimetry was also calculated based on the animal data. RESULTS: TOHP-CD3813 retained a high affinity for CD38 with a KD of 0.0826 nmol/L. [68Ga]Ga-TOHP-CD3813 was successfully synthesized at room temperature within 10 min, exhibiting optimal radiochemical properties. Preclinical assessments revealed rapid blood clearance, high CD38 affinity, and significant uptake in CD38-positive xenograft mouse models (6.50 ± 2.69%ID/g). [68Ga]Ga-TOHP-CD3813 showed pronounced accumulation in the kidneys and bladder, with moderate liver uptake, indicating its potential as a viable clinical PET radiotracer for diagnosing MM. Additionally, in first-in-human trials, [68Ga]Ga-TOHP-CD3813 PET/CT provides a substantial improvement over [18F]FDG PET/CT for the visualization of MM. CONCLUSIONS: [68Ga]Ga-TOHP-CD3813, with its high affinity, specificity, and robust imaging capabilities, rapidly and specifically accumulates in tumors with high CD38 expression, offering a significant advantage over [18F]FDG PET/CT for visualizing MM and enabling same-day PET imaging. Initial human trial results are promising, suggesting its potential as a companion diagnostic tool for optimizing CD38-targeted treatments in tumors. Ongoing larger trials aim to further confirm these findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Huang W, Wang T, Qiu Y, et al. CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies. Eur J Nucl Med Mol Imaging. 2024. PMID: 39725695. doi:10.1007/s00259-024-07036-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。